TUMOR ANALYSIS THAT helps determine THE PATIENT’S COURSE OF CARE
- SmartKidney Dx is a biomarker-based, algorithm-driven direct tissue measurement that we believe predicts the presence or risk of metastases.
- We believe it identifies patients who are candidates for additional therapy, due to undiagnosed micro-metastases by the current standard of care.
- We believe this test will help accelerate the course of treatment by reducing risk of disease progression through early intervention.
- SmartKidney Dx was developed in partnership and collaboration with Mayo Clinic and licensed with Mayo Ventures.